BioMarin Pharmaceutical Inc. (BMRN)Healthcare | Biotechnology | San Rafael, United States | NasdaqGS
56.05 USD
+0.91
(1.650%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:54 a.m. EDT
The immediate outlook is clouded by a sharp price decline over the last two years, dropping nearly 44% from the peak, with the most recent annual performance showing another significant drop. While the forward P/E suggests analysts expect a massive earnings turnaround, the current reality shows a massive gap between expectations and results, with earnings growth plummeting and quarterly profits shrinking. The lack of any dividend history eliminates income appeal entirely. Although the balance sheet remains relatively healthy compared to peers, the market is clearly pricing in a severe structural deterioration in the business model, evidenced by the multi-year price collapse. The options market confirms this fear, with traders aggressively buying downside protection while the statistical forecast model offers a weak, low-confidence bearish lean that aligns with the broader trend but lacks the conviction to suggest a reversal soon. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.111346 |
| AutoETS | 0.116426 |
| AutoARIMA | 0.116427 |
| MSTL | 0.122995 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 12.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.070 |
| Excess Kurtosis | -0.94 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 66.473 |
| Revenue per Share | 17.692 |
| Market Cap | 10,849,809,408 |
| Trailing P/E | 151.49 |
| Forward P/E | 8.45 |
| Beta | 0.22 |
| Profit Margins | 2.14% |
| Website | https://www.biomarin.com |
As of Oct. 10, 2026, 2:54 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly in the January 2027 expiration where out-of-the-money puts show significant open interest. There is a notable 'wall' of call open interest at strikes significantly above the current price (75, 90, 100), suggesting a speculative ceiling or long-term recovery thesis, but the immediate term sentiment is bearish with elevated implied volatility on downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.051792026 |
| Address1 | 770 Lindaro Street |
| All Time High | 151.75 |
| All Time Low | 3.57 |
| Ask | 57.57 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 2,543,600 |
| Average Daily Volume3 Month | 2,125,662 |
| Average Volume | 2,125,662 |
| Average Volume10Days | 2,543,600 |
| Beta | 0.215 |
| Bid | 52.0 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 32.664 |
| City | San Rafael |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 56.05 |
| Current Ratio | 2.387 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 57.58 |
| Day Low | 55.96 |
| Debt To Equity | 66.473 |
| Display Name | BioMarin Pharmaceutical |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,046,400 |
| Earnings Call Timestamp Start | 1,786,046,400 |
| Earnings Growth | -0.813 |
| Earnings Quarterly Growth | -0.814 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,044,800 |
| Earnings Timestamp Start | 1,793,044,800 |
| Ebitda | 645,318,976 |
| Ebitda Margins | 0.18943001 |
| Enterprise To Ebitda | 21.971 |
| Enterprise To Revenue | 4.162 |
| Enterprise Value | 14,178,003,968 |
| Eps Current Year | 4.6264 |
| Eps Forward | 6.63697 |
| Eps Trailing Twelve Months | 0.37 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 63.0916 |
| Fifty Day Average Change | -7.0415993 |
| Fifty Day Average Change Percent | -0.111609146 |
| Fifty Two Week Change Percent | 5.1792026 |
| Fifty Two Week High | 70.98 |
| Fifty Two Week High Change | -14.930004 |
| Fifty Two Week High Change Percent | -0.21034099 |
| Fifty Two Week Low | 49.26 |
| Fifty Two Week Low Change | 6.790001 |
| Fifty Two Week Low Change Percent | 0.13784006 |
| Fifty Two Week Range | 49.26 - 70.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 932,995,800,000 |
| Float Shares | 192,631,055 |
| Forward Eps | 6.63697 |
| Forward P E | 8.445119 |
| Free Cashflow | 85,157,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 3,221 |
| Fullday Change | 0.45000076 |
| Fullday Change Percent | 0.80285597 |
| Fullday Price | 56.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.50968 |
| Gross Profits | 1,736,295,040 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0034 |
| Held Percent Institutions | 1.03307 |
| Implied Shares Outstanding | 193,573,759 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investors.bmrn.com/index.cfm |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California. |
| Long Name | BioMarin Pharmaceutical Inc. |
| Market | us_market |
| Market Cap | 10,849,809,408 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_25605 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 72,972,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,041,642,826 |
| Number Of Analyst Opinions | 27 |
| Open | 56.43 |
| Operating Cashflow | 857,089,024 |
| Operating Margins | 0.21162 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.32 |
| Phone | 415 506 6700 |
| Pre Market Change | 0.45000076 |
| Pre Market Change Percent | 0.80285597 |
| Pre Market Price | 56.5 |
| Pre Market Time | 1,792,152,138 |
| Previous Close | 55.14 |
| Price Eps Current Year | 12.115252 |
| Price Hint | 2 |
| Price To Book | 1.7159563 |
| Price To Sales Trailing12 Months | 3.1849248 |
| Profit Margins | 0.02142 |
| Quick Ratio | 1.163 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.67857 |
| Region | US |
| Regular Market Change | 0.91 |
| Regular Market Change Percent | 1.65034 |
| Regular Market Day High | 57.58 |
| Regular Market Day Low | 55.96 |
| Regular Market Day Range | 55.96 - 57.58 |
| Regular Market Open | 56.43 |
| Regular Market Previous Close | 55.14 |
| Regular Market Price | 56.05 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 2,880,585 |
| Return On Assets | 0.03257 |
| Return On Equity | 0.011820001 |
| Revenue Growth | 0.199 |
| Revenue Per Share | 17.692 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 193,573,759 |
| Shares Percent Shares Out | 0.059499998 |
| Shares Short | 11,522,835 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,877,553 |
| Short Name | BioMarin Pharmaceutical Inc. |
| Short Percent Of Float | 0.059699997 |
| Short Ratio | 5.73 |
| Source Interval | 15 |
| State | CA |
| Symbol | BMRN |
| Target High Price | 124.0 |
| Target Low Price | 60.0 |
| Target Mean Price | 91.59259 |
| Target Median Price | 90.0 |
| Total Cash | 874,004,992 |
| Total Cash Per Share | 4.515 |
| Total Debt | 4,202,200,064 |
| Total Revenue | 3,406,614,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.37 |
| Trailing P E | 151.48648 |
| Trailing Peg Ratio | 0.3642 |
| Triggerable | 1 |
| Two Hundred Day Average | 58.5844 |
| Two Hundred Day Average Change | -2.534401 |
| Two Hundred Day Average Change Percent | -0.04326068 |
| Type Disp | Equity |
| Volume | 2,880,585 |
| Website | https://www.biomarin.com |
| Zip | 94,901 |